A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Inclusion Criteria:

• Males or females weighing ≥10 kg and ≥2 and <18 years old at the time of consent forscreening.

• Have moderate to severe UC.

• Have failed corticosteroids, biologics, (for example, anti-tumor necrosis factor (TNF) antibodies or anti-integrin antibodies), immunomodulators (for example,azathioprine, thiopurines or methotrexate) or Janus Kinase (JAK)-Inhibitortreatment.

• Have UC at least 3 months in duration before baseline, which includes endoscopicevidence of UC corroborated by a histopathology report.

Exclusion Criteria:

• Have Crohn's disease, Inflammatory Bowel Disease Unclassified, ulcerative proctitisor primary sclerosing cholangitis.

• Have immune deficiency syndrome.

• Previous bowel resection or intestinal surgery.

• Evidence of toxic megacolon.

• History or current evidence of cancer of the gastrointestinal tract.